http://rdf.ncbi.nlm.nih.gov/pubchem/reference/6030181

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Multicenter Study
endingPage 46
issn 1340-6868
1880-4233
issueIdentifier 1
pageRange 39-46
publicationName Breast cancer (Tokyo, Japan)
startingPage 39
bibliographicCitation Noguchi E, Tamura K, Hattori M, Horiguchi J, Sato N, Kanatani K, Matsunaga K, Iwata H, Fujiwara Y. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. Breast Cancer. 2019 Jan;26(1):39–46. doi: 10.1007/s12282-018-0887-z. PMID: 30039339.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f209744d251c5878f8530070a8a88975
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04a45e0838242b1a205aacfef1492369
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7bcc1706acedb2a13b953160ffe1f3eb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03537939cdaacbebf0ab16280da8e144
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8160a05b4b709ba7a067f2bdea608938
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_35c4787d3f7ae65d4865356eed927e00
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a6ca9f69dc8fe3d542c3bc71d3e2d2db
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e717c369c2a4ea2b1c7d4aa11c35a4dd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1229-5446
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc650fb8f34d2718978912ed20cd01ac
date 2018-07-23^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1007/s12282-018-0887-z
https://pubmed.ncbi.nlm.nih.gov/30039339
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21858
https://portal.issn.org/resource/ISSN/1340-6868
https://portal.issn.org/resource/ISSN/1880-4233
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://scigraph.springernature.com/
https://www.crossref.org/
title Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
discusses http://id.nlm.nih.gov/mesh/M0466011
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0495206
http://id.nlm.nih.gov/mesh/M0291428
http://id.nlm.nih.gov/mesh/M0548409
http://id.nlm.nih.gov/mesh/M0013148
http://id.nlm.nih.gov/mesh/M0028048
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D061067Q000627
http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D001943Q000188
http://id.nlm.nih.gov/mesh/D000068878Q000627
http://id.nlm.nih.gov/mesh/D008453Q000031
http://id.nlm.nih.gov/mesh/D003967Q000453
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000971Q000493
http://id.nlm.nih.gov/mesh/D004334
http://id.nlm.nih.gov/mesh/D003967Q000139
http://id.nlm.nih.gov/mesh/D008453Q000627
http://id.nlm.nih.gov/mesh/D008453Q000493
http://id.nlm.nih.gov/mesh/D018719Q000378
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D007564Q000453
http://id.nlm.nih.gov/mesh/D000068878Q000493
http://id.nlm.nih.gov/mesh/D014057
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D001943Q000000981
http://id.nlm.nih.gov/mesh/D001943Q000097
http://id.nlm.nih.gov/mesh/D001943Q000473
http://id.nlm.nih.gov/mesh/D008279
http://id.nlm.nih.gov/mesh/D001940Q000000981
http://id.nlm.nih.gov/mesh/D009364
http://id.nlm.nih.gov/mesh/D061067Q000493
http://id.nlm.nih.gov/mesh/D001940Q000473
http://id.nlm.nih.gov/mesh/D000080044
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D066066
http://id.nlm.nih.gov/mesh/D008875
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.6.1.1
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b60e7841ce141c73cb0fd4d93079c52d
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102

Showing number of triples: 1 to 73 of 73.